Assessment of thrombin generation: Useful or hype?

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 1, 2009, Pages 104-110

  Adams, Murray ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Bleeding; Hemostasis; Laboratory testing; Thrombin generation assays; Thrombosis

Indexed keywords

REAGENT; THROMBIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; HYPOCOAGULABILITY; MEDICAL LITERATURE; MONITORING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCREENING; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOSIS;

BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MULTICENTER STUDIES AS TOPIC; PLATELET ACTIVATION; THROMBIN;

EID: 63149129600     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1214153     Document Type: Review

References (52)

1. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74:134-138
2. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008;34: 604-611
3. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312
4. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a a biochemical amplifier. Nature 1964;202:498-499
5. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977;74:5260-5264
6. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985;66:204-212
7. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991;253:909-912
8. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965
9. McVey JH. Tissue factor pathway. Best Pract Res Clin Haematol 1999;12:361-372
10. Crawley JT, Zanardelli S, Chion CK, Lane DA. The central role of thrombin in hemostasis. J Thromb Haemost 2007;5(Suppl 1):95-101
11. Righini M, Perrier A, De Moerloose P, Bounameaux H. D-dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008;6:1059-1071
12. Stegnar M, Vene N, Bozic M. Do haemostasis activation markers that predict cardiovascular disease exist? Pathophysiol Haemost Thromb 2003;33:302-308
13. Macfarlane RG, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol 1953;6:3-8
14. Pitney WR, Dacie JV. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia. J Clin Pathol 1953;6:9-14
15. Baglin T. The measurement and application of thrombin generation. Br J Haematol 2005;130:653-661
16. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-624
17. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986;56:9-17
18. Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW. Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. Br J Haematol 2007;139:106-112
19. Stief TW. Influence of the surface on thrombin generation. Int J Lab Hematol 2008;30:269-277
20. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006;96:553-561
21. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008;142:889-903
22. Berntop E, Salvagno GL. Standardization and clinical utility of thrombin generation assays. Semin Thromb Hemost 2008;34:670-682
23. Dargaud Y, Beguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005;93:475-480
24. Varadi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004;10(Suppl 2):17-21
25. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005;11:326-334
26. Turecek PL, Varadi K, Keil B, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003;33:16-22
27. Rugeri L, Beguin S, Hemker C, et al. Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica 2007;92:1639-1646
28. Beguin S, Keularts I, Al Dieri R, et al. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost 2004;2:170-176
29. Beguin S, Kumar R, Keularts I, et al. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999;93:564-570
30. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-874
31. Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002;88:576-582
32. al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004;2:1395-1401
33. Al Dieri R, Alban S, Beguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006;4:83-89
34. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007;5:886-888
35. Gerotziafas GT, Depasse F, Chakroun T, et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 2004;15:149-156
36. Beilfu ACommentStCommentEndCommentBody, Grandoch M, Wenzel F, et al. Differential effects of factor IIa inhibitors on the endogenous thrombin potential. Ther Drug Monit 2008; September 26 (Epub ahead of print)
37. Wegert W, Graff J, Kaiser D, et al. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther 2002;40:135-141
38. Ignjatovic V, Summerhayes R, Yip YY, Monagle P. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults. Thromb Res 2008;122:709-714
39. Gatt A, van Veen JJ, Woolley AM, et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008;100:350-355
40. Brodin E, Seljeflot I, Arnesen H, et al. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res 2009;123:573-579
41. Gatt A, van Veen JJ, Bowyer A, et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic international normalized ratio is not due to inflammation. Br J Haematol 2008;142:946-952
42. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002;88:5-11
43. Duchemin J, Pittet JL, Tartary M, et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994;71:331-338
44. Gardiner C, Machin SJ, Mackie IJ. Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000). Int J Lab Hematol 2008;30:261-268
45. Tchaikovski SN, van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007;98:1350-1356
46. Regnault V, Beguin S, Lecompte T. Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability. Pathophysiol Haemost Thromb 2003;33:23-29
47. Rosenkranz A, Hiden M, Leschnik B, et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 2008;99:331-337
48. Regnault V, Beguin S, Wahl D, et al. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003;89:208-212
49. Lecompte T, Wahl D, Perret-Guillaume C, et al. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica 2007;92:714-715
50. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008;54:2042-2048
51. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008;6:1720-1725
52. van Hylckama Vlieg A, Christiansen SC, Luddington R, et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007;138:769-774